Catalent Cell and Gene Content

1. Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids 8/14/2025

   Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.

2. UpTempo℠: Seamless Transitions From Bench To CGT Applications 6/19/2025

   Accelerate cell and gene therapy development with high-yield, regulatory-compliant plasmid DNA manufacturing that shortens timelines, minimizes risks, and streamlines your supply chain.

3. From Platform To Patient: Streamlining Gene Therapy Development 12/5/2024

   Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

4. 07.14.23 -- Accelerate Development Timelines With Improved Characterization Methods 7/14/2023

   07/14/23 Outsourced Pharma Newsletter

5. UpTempo℠ AAV Platform Process

   Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

6. Quantifying Cell Response With Duplex RT-qPCR

   Discover a new potency bioassay using RT-qPCR to assess relative transcription activity, and learn more about the advantages and limitations of transcriptional assays versus reporter gene assays.

7. Exploring An Integrated Solution For AAV Vector Clinical Production

   Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.

8. Accelerating Your Gene Therapy: Not All Platforms Are Created Equal

   Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.